FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Para fines de investigación únicamente. Aviso completo →

Volver a Biblioteca de Investigación
PubMedRandomized Controlled TrialSujetos Humanos

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

Rosenstock Julio, Wysham Carol, Frías Juan P, Kaneko Shizuka, Lee Clare J, Fernández Landó Laura, Mao Huzhang, Cui Xuewei, Karanikas Chrisanthi A, Thieu Vivian T
Lancet (London, England)2021DOI: 10.1016/S0140-6736(21)01324-6
tirzepatideGIP receptor agonistGLP-1 receptor agonist

Puntuación de Calidad

7/10

Citas

0

Sujetos

Humano

Análisis de Peptide Contacts

Study Design

As a randomized controlled trial, this study represents the highest tier of clinical evidence. The randomized design controls for confounding variables, making causal inferences more robust than observational studies.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

The results for tirzepatide, GIP receptor agonist, GLP-1 receptor agonist are encouraging. Critically, these findings come from human data — not animal models or in-vitro work — which makes them directly relevant to clinical applications. The study design adds significant weight to these conclusions.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for tirzepatide, GIP receptor agonist, GLP-1 receptor agonist. If you're tracking the research landscape for these compounds, this paper deserves a close read.

Encuentros Clave

The study found that tirzepatide, a dual GIP and GLP-1 receptor agonist, showed significant improvements in glycemic control and body weight compared to placebo in patients with type 2 diabetes inadequately controlled by diet and exercise alone.

Limitaciones

The study had a relatively short duration of 40 weeks, which may not fully capture long-term effects or safety issues. Additionally, the trial excluded participants already on injectable diabetes therapy, limiting generalizability to all patients with type 2 diabetes.

Cómo Interpretar esta Investigación

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Examine the primary endpoint — did the study measure what actually matters clinically, or a proxy marker?

4

Statistical significance (p < 0.05) does not always mean clinical significance. Look at the actual effect size.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Análisis de Peptide Contacts

Highlighting the potential of tirzepatide as a novel dual GIP and GLP-1 receptor agonist for managing type 2 diabetes, focusing on its efficacy and safety profile.

tirzepatideGIP receptor agonistGLP-1 receptor agonist

Novel Dual GIP and GLP-1 Receptor Agonist Shows Promise in Type 2 Diabetes Management

Published: May 17, 2026 | Source: Lancet (London, England) (2021) | Category: tirzepatide, GIP receptor agonist, GLP-1 receptor agonist

Overview

A recent study published in the Lancet has shown that a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist called tirzepatide can significantly improve glycemic control and body weight in patients with type 2 diabetes who are not adequately managed by diet and exercise alone. This research highlights the potential of this new class of drugs for managing a condition that affects millions globally.

Study Background

Type 2 diabetes is a chronic illness characterized by high blood sugar levels due to insulin resistance or insufficient insulin production. Despite advancements in treatment, many patients struggle to achieve optimal glycemic control with existing therapies. The development of tirzepatide aims to address this gap by targeting both GIP and GLP-1 receptors, which are involved in glucose regulation and weight management.

What the Research Found

The SURPASS-1 trial was a 40-week, double-blind, randomized, placebo-controlled phase 3 study conducted across multiple countries. Participants were adults with type 2 diabetes inadequately controlled by diet and exercise alone who had not previously used injectable diabetes therapies. They were randomly assigned to receive once-weekly doses of tirzepatide (5 mg, 10 mg, or 15 mg) or placebo.

The primary outcome was the mean change in glycated hemoglobin (HbA1c), a measure of long-term blood sugar control. The study found that all three doses of tirzepatide led to significant reductions in HbA1c compared to placebo. Additionally, participants treated with tirzepatide experienced substantial weight loss and showed no increased risk of hypoglycaemia.

What This Means for Peptide Users

The results suggest that tirzepatide could be a promising new option for patients who have not responded well to traditional diabetes management strategies. Its dual mechanism of action targeting both GIP and GLP-1 receptors may offer enhanced efficacy in improving glycemic control and body weight, which are critical factors in managing type 2 diabetes.

Limitations and Caveats

While the study demonstrated significant benefits with tirzepatide, it had several limitations. The trial's relatively short duration of 40 weeks means that long-term safety and efficacy remain uncertain. Additionally, the exclusion of patients already on injectable therapies limits the generalizability of these findings to a broader patient population.

How This Compares to Previous Research

Previous studies have focused primarily on GLP-1 receptor agonists alone for type 2 diabetes management. The introduction of tirzepatide represents an advancement by targeting both GIP and GLP-1 receptors, potentially offering superior therapeutic effects compared to single-receptor agonists.

Our Analysis

The SURPASS-1 trial provides compelling evidence for the efficacy and safety profile of tirzepatide as a novel dual receptor agonist in type 2 diabetes management. However, further research is needed to confirm its long-term benefits and assess its suitability across diverse patient populations, including those already on injectable therapies.

Key Takeaways

  • Efficacy: Tirzepatide showed significant improvements in glycemic control and body weight compared to placebo.
  • Safety: The drug demonstrated a safety profile consistent with GLP-1 receptor agonists without increased hypoglycaemia risk.
  • Limitations: Short study duration and exclusion of patients on injectable therapies limit broader applicability.

Original Source

Citation: Rosenstock Julio, Wysham Carol, Frías Juan P et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.. Lancet (London, England). DOI: 10.1016/S0140-6736(21)01324-6

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota del Editor

Este análisis fue escrito por el equipo de investigación de Peptide Contacts para hacer hallazgos complejos accesibles a la comunidad de péptidos. Se anima a los lectores a revisar el paper fuente para metodología y datos completos. Para más sobre tirzepatide, explore nuestros guias de investigación.

Cita

Rosenstock Julio, Wysham Carol, Frías Juan P et al.. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/S0140-6736(21)01324-6

Ver texto completo en PubMed

Papers Relacionados

Explorar más

Este contenido se deriva de investigación revisada por pares para fines educativos solo. No constituye consejo médico. Consulte siempre a un proveedor de atención médica calificado antes de usar cualquier terapia basada en péptidos.